University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Selected Publication:

Open Access Logo

Publication type: Journal Article
Document type: Review

Year: 2018

Author(s): Valent, P; Büsche, G; Theurl, I; Uras, IZ; Germing, U; Stauder, R; Sotlar, K; Füreder, W; Bettelheim, P; Pfeilstöcker, M; Oberbauer, R; Sperr, WR; Geissler, K; Schwaller, J; Moriggl, R; Béné, MC; Jäger, U; Horny, HP; Hermine, O

Title: Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Source: Haematologica. 2018; 103(10):1593-1603



Authors Vetmeduni Vienna:

Moriggl Richard
Uras Jodl Iris

Vetmed Research Units
Institute of Pharmacology and Toxicology
Unit for Functional Cancer Genomics


Abstract:
Pathological erythropoiesis with consequent anemia is a leading cause of symptomatic morbidity in internal medicine. The etiologies of anemia are complex and include reactive as well as neoplastic conditions. Clonal expansion of erythroid cells in the bone marrow may result in peripheral erythrocytosis and polycythemia but can also result in anemia when clonal cells are dysplastic and have a maturation arrest that leads to apoptosis and hinders migration, a constellation typically seen in the myelodysplastic syndromes. Rarely, clonal expansion of immature erythroid blasts results in a clinical picture resembling erythroid leukemia. Although several mechanisms underlying normal and abnormal erythropoiesis and the pathogenesis of related disorders have been deciphered in recent years, little is known about specific markers and targets through which prognosis and therapy could be improved in anemic or polycythemic patients. In order to discuss new markers, targets and novel therapeutic approaches in erythroid disorders and the related pathologies, a workshop was organized in Vienna in April 2017. The outcomes of this workshop are summarized in this review, which includes a discussion of new diagnostic and prognostic markers, the updated WHO classification, and an overview of new drugs used to stimulate or to interfere with erythropoiesis in various neoplastic and reactive conditions. The use and usefulness of established and novel erythropoiesis-stimulating agents for various indications, including myelodysplastic syndromes and other neoplasms, are also discussed.


© University of Veterinary Medicine ViennaHelp and Downloads